KR900002794A - TGF-β를 이용한 건선 치료방법 - Google Patents

TGF-β를 이용한 건선 치료방법 Download PDF

Info

Publication number
KR900002794A
KR900002794A KR1019890011006A KR890011006A KR900002794A KR 900002794 A KR900002794 A KR 900002794A KR 1019890011006 A KR1019890011006 A KR 1019890011006A KR 890011006 A KR890011006 A KR 890011006A KR 900002794 A KR900002794 A KR 900002794A
Authority
KR
South Korea
Prior art keywords
proliferation
tgf
epidermal cells
inhibiting
keratinocytes
Prior art date
Application number
KR1019890011006A
Other languages
English (en)
Other versions
KR920002163B1 (ko
Inventor
알. 트와르직 다니엘
에프. 퍼치오 안토니
이. 랭컬리스 제인
스티븐스 빅터
Original Assignee
아이삭 자아코브스키
온코겐 어 리미티드 파트너쉽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이삭 자아코브스키, 온코겐 어 리미티드 파트너쉽 filed Critical 아이삭 자아코브스키
Publication of KR900002794A publication Critical patent/KR900002794A/ko
Application granted granted Critical
Publication of KR920002163B1 publication Critical patent/KR920002163B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

TGF-β를 이용한 건선 치료방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 원숭이의(시미안) TGF-βcDNA의 뉴클레오티드 배열과 이로부터 연역된 아미노산 배열을 나타낸다. pTGF-β의 1600bp 삽입물을 M13mp18과 M13mp19 클로닝 벡터에 서브클론시키고(Yanisch-Perron 외, 1985) 디데옥시 체인 종결법(Sanger외, 1977)을 이용하여 양 사슬의 배열을 분석하였다. 인간의 DNA 배열과 원숭이의 DNA 배열은 표시된 곳을 제외하고는 동일하며(도트); 인간과 원숭이의 단백질 사이의 아미노산 차이를 윗줄에 나타내었다. 성숙한 TGF-β배열을 박스안에 표시하고 시그날 펩티드는 윗줄을 그어 표시하였다. 5'미번역 영역중의 팔린드롬(palindrome) 또한 윗줄을 그어 표시하였다.
제2도는 프란쯔(Franz) 확산 챔버를 나타낸 도면,
제3도는 국소 TGF-β를 받은 모든 챔버의 수집된 섭수체 용액으로부터 회수된 (35S)HPLC 크로마토그래프를 나타낸다. 용매로 PBS를 사용하여 겔침투컬럼에서 분리시켰다. 미리 주사한 표준물에 기초하여 피크의 대략적인 분자량을 표시하였다.
제4도는 4가지 피부 크럼베이스로부터의 TGF-β회부백분율을 나타내는도면.

Claims (10)

  1. #TGF-β의 완전한 배열의 최소한 8개의 연속적인 아미노산으로 이루어진 형질전환 성장인자-베타(TGF-β) 또는 그의 단편을 하나 이상 필수적으로 포함하면서, 표피세포의 증식을 억제할 수 있는 조성물을 상기의 표피세포와 접촉시키는 것을 특징으로 하는 표피세포의 증식억제방법.
  2. 제1항에 있어서, 상기 표피세포가 케라틴세포인 것이 특징인 표피세포의 증식억제방법.
  3. 제1항에 있어서, 상기형질전환 성장인자 베타가 TGF-β1이나 TGF-β2로 되는 것이 특징인 표피세포의 증식억제 방법.
  4. 형질전환 성장인자-베타의 완전한 배열중에 포함되는 최소한 8개의 연속적인 아미노산으로 이루어지면서 케라틴세포의 증식을 억제할 수 있는 폴리펩티드를 필수적으로 함유하는 시토카인 유도성 증식의 억제자를 상기 케라틴세포와 접촉시키는 것을 특징으로 하는 케라틴세포의 시코카인 유도성 증식억제방법.
  5. 제4항에 있어서, 상기 시토카인이 TGF-α, 인터류킨 1, 및 EGF중 적어도 하나인것이 특징인 케라틴세포의 시토카인 유도성 증식억제방법.
  6. 복수의 초고속 증식 표피세포들을 TGF-β1이나, TGF-β2 또는 이들의 콘지너(congener)로 된 폴리펩티드의 증식억제량과 접촉시킴을 특징으로하는 복수의 초고속 증식 표피세포의 증식억제방법.
  7. 생리적으로 허용되는 담체중에 최소한 하나이상의 형질전환 성장인자-베타 또는 그의 콘지너의 세표 증식억제량이 포함된 케라틴세포 증식억제조성물.
  8. 제7항에 있어서, 상기의 생리적으로 허용되는 담체에 표피 침투촉진제가 추가로 포함됨을 특징으로 하는 케라틴세포 증식억제조성물.
  9. 제8항에 있어서, 상기 촉진제가 약 5내지 약 50%의 디메틸술폭시드로 된것이 특징인 케라틴세포 증식억제조성물.
  10. 제9항에 있어서, 상기 농도가 약 25%인 것이 특징인 케라틴세포 증식억제조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890011006A 1988-08-05 1989-08-01 TGF-β를 이용한 건선 치료방법 KR920002163B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22913388A 1988-08-05 1988-08-05
US229,133 1988-08-05

Publications (2)

Publication Number Publication Date
KR900002794A true KR900002794A (ko) 1990-03-23
KR920002163B1 KR920002163B1 (ko) 1992-03-19

Family

ID=22859955

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890011006A KR920002163B1 (ko) 1988-08-05 1989-08-01 TGF-β를 이용한 건선 치료방법

Country Status (4)

Country Link
EP (1) EP0353772A3 (ko)
JP (1) JPH02167231A (ko)
KR (1) KR920002163B1 (ko)
IL (1) IL91186A0 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN273695A0 (en) * 1995-05-02 1995-05-25 University Of Queensland, The Aluminium alloy powder blends and sintered aluminium alloys
US6133416A (en) * 1996-08-23 2000-10-17 The University Of Texas System Board Of Regents Inhibition of cell growth by an anti-proliferative factor
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
AU1521501A (en) * 1999-11-10 2001-06-06 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders
JP5890100B2 (ja) * 2011-02-09 2016-03-22 雪印メグミルク株式会社 皮膚コラーゲン産生促進剤
EP2765186A4 (en) 2011-05-31 2015-05-27 Snu R&Db Foundation STRUCTURE FOR TEXTILE GENERATION AND METHOD OF MANUFACTURING THEREOF
US9820953B2 (en) * 2016-02-26 2017-11-21 Omni Bioceutical Innovations, Inc. Compositions of bioactive fulvate fractions and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0105014B1 (en) * 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
EP0269408A3 (en) * 1986-11-26 1989-08-30 Genentech, Inc. Tgf-beta in the treatment of inflammatory disorders
AU2844889A (en) * 1988-01-22 1989-07-27 Collagen Corporation Method for suppressing the growth of normal and cancer cells
KR101363301B1 (ko) * 2005-12-23 2014-02-18 롤리크 아게 광가교결합성 재료
JP5633677B2 (ja) * 2009-09-04 2014-12-03 Jsr株式会社 液晶配向剤

Also Published As

Publication number Publication date
KR920002163B1 (ko) 1992-03-19
JPH02167231A (ja) 1990-06-27
EP0353772A3 (en) 1990-07-04
IL91186A0 (en) 1990-03-19
EP0353772A2 (en) 1990-02-07

Similar Documents

Publication Publication Date Title
Thomas et al. Fibroblast growth factors: broad spectrum mitogens with potent angiogenic activity
Thomas et al. An octamer of histones in chromatin and free in solution.
Aggarwal et al. Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization.
PT720482E (pt) Prosaposina e peptidos derivados da citocina utilizados como agentes
RU95115239A (ru) Аналог эритропоэтина
KR900002794A (ko) TGF-β를 이용한 건선 치료방법
AU7681687A (en) Expression of platelet-derived growth factor and analogues
LV10490A (lv) DNS seciba kas kode proteinus ar HUSI-tipa inhibitoru biologisko aktivitati mineto proteinu iegusanas biotehnologiskais panemiens farmaceitiskas kompozicijas kas satur minetos proteinus
PT100651A (pt) Muteinas da interleucina 6 (il-6) isentas de cisteina
US5070188A (en) Acylated epidermal growth factor
Shibata et al. Purification and characterization of pancreatic secretory trypsin inhibitor in human gastric mucosa
WO1997014966B1 (en) Method of activating a novel ligand regulatory pathway
Suzuki et al. Amino acid sequence of myoglobin from the chiton Liolophura japonica and a phylogenetic tree for molluscan globins
EP0759069B1 (en) Beta taipoxin as a cell growth factor and method
AU7336687A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
KR930004326A (ko) 콘드로모듈린-ii 단백질
Dios et al. Sub-Saharan genetic contribution in Morocco: microsatellite DNA analysis
DE68918197D1 (de) Methode zur Herstellung von rekombinantem menschlichem beta-Interleukin-1 in homogener Form.
Lemmon PURIFICATION AND CHARACTERIZATION OF BOVINE FIBROBLAST GROWTH FACTORS.
Ansay Instability of the bovine MOR-2AB (mitochondrial malate: NAD oxidoreductase) heterodimeric molecule of heterozygous subjects after isoelectric focusing
菅田恵子 Purification and Heterogeneity of Human Chorionic Gonadotropin
Davis Sciatic nerve protein composition in normal and dystrophic C57BL/6J mice
Hotta et al. Demonstration of early anagen-specific stimulatory factors within skin tissue for in vitro mesenchymal-epithelial interaction in collagen embedded hair follicle mixed culture
Iwasaki et al. Human keratinocytes synthesize linkin (microthread-like protein)
Schaefer et al. Heparin and heparansulfate modulate cell-matrix interactions of fibroblasts and endothelial cells in vitro and interact with specific binding sites

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19950310

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee